|[September 10, 2013]
Research and Markets: High Triglyceridemia - Pipeline Review, H2 2013
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/fj6jfr/high)
has announced the addition of the "High
Triglyceridemia - Pipeline Review, H2 2013" report to their
'High Triglyceridemia - Pipeline Review, H2 2013', provides an overview
of the indication's therapeutic pipeline. This report provides
information on the therapeutic development for High Triglyceridemia,
complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the
therapeutic development for High Triglyceridemia.
- A sapshot of the global therapeutic scenario for High Triglyceridemia.
- A review of the High Triglyceridemia products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging
from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
- Coverage of the High Triglyceridemia pipeline on the basis of route of
administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Isis Pharmaceuticals, Inc.
Astellas Pharma Inc.
Amarin Corporation plc
Catabasis Pharmaceuticals, Inc.
Cardax Pharmaceuticals, Inc.
FORMAC Pharmaceuticals N.V.
For more information visit http://www.researchandmarkets.com/research/fj6jfr/high
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]